These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25651720)

  • 1. Routine coagulation tests are not useful as a screening tool for the FII G20210A polymorphism.
    Rolla R; Pergolini P; Vidali M; Pollarolo P; Appiani A; Cerutti C; Manzini M; Crisci A; Bellomo G
    Clin Lab; 2014; 60(10):1725-33. PubMed ID: 25651720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.
    Shirts BH; Rodgers GM; Smock KJ
    Thromb Res; 2012 Sep; 130(3):e134-8. PubMed ID: 22542363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant.
    Delahousse B; Gilbert M; Nicham F; Thirion C; Giraudeau B; Gruel Y
    Blood Coagul Fibrinolysis; 2002 Jul; 13(5):465-70. PubMed ID: 12138376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis.
    Gemmati D; Serino ML; Moratelli S; Tognazzo S; Ongaro A; Scapoli GL
    Haemostasis; 2001; 31(2):99-105. PubMed ID: 11684865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden.
    Rahimi Z; Vaisi-Raygani A; Nagel RL; Muniz A
    J Thromb Thrombolysis; 2008 Jun; 25(3):288-92. PubMed ID: 17619828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran.
    Rahimi Z; Vaisi-Raygani A; Mozafari H; Kharrazi H; Rezaei M; Nagel RL
    J Thromb Thrombolysis; 2008 Jun; 25(3):280-3. PubMed ID: 17700999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular mechanisms of inherited thrombophilia.
    März W; Nauck M; Wieland H
    Z Kardiol; 2000 Jul; 89(7):575-86. PubMed ID: 10957782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: consecutive survivors and population-based controls.
    Krajcoviechova A; Wohlfahrt P; Mayer O; Vanek J; Hajkova J; Hlinovsky D; Kvasnicka T; Tremblay J; Hamet P; Filipovsky J; Kvasnicka J; Cifkova R
    Atherosclerosis; 2015 Jun; 240(2):446-52. PubMed ID: 25897999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia.
    Martinelli I; Battaglioli T; Razzari C; Mannucci PM
    J Thromb Haemost; 2007 Jan; 5(1):98-101. PubMed ID: 17067362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution.
    Mazoyer E; Ripoll L; Gueguen R; Tiret L; Collet JP; dit Sollier CB; Roussi J; Drouet L;
    Blood Coagul Fibrinolysis; 2009 Oct; 20(7):503-10. PubMed ID: 19730248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAl-1 4G/5G and their combinations in a group of 1450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay)].
    Kvasnicka J; Hájková J; Bobcíková P; Kvasnicka T; Dusková D; Poletínová S; Kieferová V
    Cas Lek Cesk; 2012; 151(2):76-82. PubMed ID: 22515013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.
    Couturaud F; Duchemin J; Leroyer C; Delahousse B; Abgrall JF; Mottier D;
    Thromb Haemost; 2008 Jan; 99(1):223-8. PubMed ID: 18217158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombin A19911G polymorphism and the risk of venous thromboembolism.
    Martinelli I; Battaglioli T; Tosetto A; Legnani C; Sottile L; Ghiotto R; Mannucci PM
    J Thromb Haemost; 2006 Dec; 4(12):2582-6. PubMed ID: 16981886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations.
    Couto E; Nomura ML; Barini R; Pinto e Silva JL
    Sao Paulo Med J; 2005 Nov; 123(6):286-8. PubMed ID: 16444389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening.
    Fábregues F; Tàssies D; Reverter JC; Carmona F; Ordinas A; Balasch J
    Fertil Steril; 2004 Apr; 81(4):989-95. PubMed ID: 15066453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor.
    Pruner I; Farm M; Tomic B; Gvozdenov M; Kovac M; Miljic P; Soutari NMH; Antovic A; Radojkovic D; Antovic J; Djordjevic V
    Clin Chem; 2020 Feb; 66(2):379-389. PubMed ID: 32040579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loop-mediated isothermal amplification (LAMP)-based method for detecting factor V Leiden and factor II G20210A common variants.
    Luca Tiscia G; Colaizzo D; Vergura P; Favuzzi G; Chinni E; Vandermeulen C; Detemmerman L; Grandone E
    J Thromb Thrombolysis; 2020 Nov; 50(4):908-912. PubMed ID: 32557225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
    Baig MA
    Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [G20210A transition in the prothrombin gene and venous thromboembolic disease].
    Trillot N; Zawadzki C; Watel A; Jude B
    Rev Med Interne; 2000 Oct; 21(10):911-4. PubMed ID: 11075405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.